非戈替尼治疗溃疡性结肠炎的疗效与安全性:日本真实世界多中心回顾性研究
这项日本多中心回顾性研究纳入238例溃疡性结肠炎患者,54%曾使用生物制剂/JAK抑制剂,评估非戈替尼的临床缓解、应答、无激素缓解及内镜改善,并记录不良事件。中位随访28周时临床缓解率39.9%,带状疱疹3例(1.3%),无血栓或死亡报告。
要点
- 10、26、58周临床缓解率分别为47%、55.8%、64.6%(符合方案分析)。
- 中位随访28周时临床缓解39.9%、临床应答54.7%、无激素缓解36.5%。
- 初治与经治患者缓解率相当,带状疱疹3例(1.3%),无血栓或死亡。
核心结论
- 真实世界数据表明非戈替尼治疗溃疡性结肠炎具有有利的临床与安全性结局。
研究设计与样本
- 多中心回顾性研究,纳入2022年3月至2023年9月间开始非戈替尼治疗的238例溃疡性结肠炎患者。
主要发现
- 54%的患者既往暴露于生物制剂/JAK抑制剂,基线部分Mayo评分中位5(IQR 3-6),SCCAI中位4(IQR 2-7)。
- 符合方案分析中10、26、58周临床缓解率分别为47%(70/149)、55.8%(48/86)、64.6%(31/48)。
- 中位随访28周(IQR 10-54)、停药率39%时,临床缓解39.9%(81/203)、临床应答54.7%(111/203)、无激素缓解36.5%(74/203)、内镜改善43.5%(10/23)。
- 上述缓解率在生物制剂/JAK抑制剂初治与经治患者间相当。
- 3例(1.3%)发生带状疱疹感染,未报告血栓或死亡病例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: While filgotinib, an oral Janus kinase (JAK) 1 preferential inhibitor, is approved for moderately to severely active ulcerative colitis (UC), real-world studies assessing its short- and long-term efficacy and safety are limited. METHODS: This is a multicenter, retrospective study of UC patients who started filgotinib between March 2022 and September 2023. The primary outcome was clinical remission, defined as a partial Mayo score ≤1 with a rectal bleeding score of 0, or Simple Clinical Colitis Activity Index (SCCAI) ≤2 with a blood-in-stool score of 0. Secondary outcomes included clinical response, corticosteroid-free remission, and endoscopic improvement. Outcomes were assessed at 10, 26, and 58 weeks based on patients with available follow-up. Adverse events were evaluated. RESULTS: We identified 238 UC patients and 54% had prior exposure to biologics/JAK inhibitors. The median baseline partial Mayo score and SCCAI were 5 (IQR 3-6) and 4 (IQR 2-7). Clinical remission rates based on per-protocol analysis at 10, 26, and 58 weeks were 47% (70/149), 55.8% (48/86), and 64.6% (31/48), respectively. At a median follow-up of 28 weeks (IQR 10-54) with a discontinuation rate of 39%, the rates of clinical remission, clinical response, corticosteroid-free remission, and endoscopic improvement were 39.9% (81/203), 54.7% (111/203), and 36.5% (74/203), and 43.5% (10/23), respectively. These rates were comparable between biologic/JAK inhibitor-naïve and -experienced patients. While three patients (1.3%) developed herpes zoster infection, no cases of thrombosis or death were reported. CONCLUSIONS: Real-world data demonstrate favourable clinical and safety outcomes of filgotinib for UC.
引用
- Akiyama S, Yokoyama K, Yagi S, et al. Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan. Aliment Pharmacol Ther. 2024. PMID: 38494867. doi:10.1111/apt.17961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。